Personalis (NASDAQ:PSNL) Hits New 52-Week High – Still a Buy?

Personalis, Inc. (NASDAQ:PSNL)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $14.83 and last traded at $14.34, with a volume of 4577511 shares trading hands. The stock had previously closed at $13.62.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. Wall Street Zen lowered shares of Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. BTIG Research reduced their target price on Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Finally, Morgan Stanley lowered their price target on Personalis from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Personalis Trading Up 0.9%

The company has a market cap of $1.48 billion, a P/E ratio of -13.83 and a beta of 2.24. The company’s fifty day moving average is $9.62 and its 200 day moving average is $8.57.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The business had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. Analysts anticipate that Personalis, Inc. will post -1.06 EPS for the current year.

Insider Transactions at Personalis

In other news, CFO Aaron Tachibana sold 4,982 shares of the business’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $14.00, for a total value of $69,748.00. Following the completion of the sale, the chief financial officer owned 198,833 shares of the company’s stock, valued at approximately $2,783,662. The trade was a 2.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $13.15, for a total value of $1,315,000.00. Following the transaction, the chief executive officer owned 235,986 shares in the company, valued at approximately $3,103,215.90. The trade was a 29.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 335,032 shares of company stock valued at $4,091,929. 4.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after buying an additional 2,395 shares during the last quarter. Dynamic Technology Lab Private Ltd grew its holdings in Personalis by 75.6% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after acquiring an additional 33,044 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Personalis by 55.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after acquiring an additional 101,706 shares during the last quarter. Focus Partners Wealth purchased a new position in shares of Personalis in the first quarter valued at about $47,000. Finally, JPMorgan Chase & Co. increased its position in shares of Personalis by 505.6% in the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock valued at $193,000 after acquiring an additional 24,621 shares during the period. 61.91% of the stock is owned by hedge funds and other institutional investors.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.